Practice
Buprenorphine–naloxone
Tina Hu, Larry Nijmeh and Adam Pyle
CMAJ November 26, 2018 190 (47) E1389; DOI: https://doi.org/10.1503/cmaj.180776
Tina Hu
Department of Family and Community Medicine (Hu, Nijmeh, Pyle), University of Toronto, Toronto, Ont.; Department of Emergency Medicine and Critical Care (Nijmeh, Pyle), Lakeridge Health, Oshawa, Ont.; Department of Family Medicine (Nijmeh, Pyle), Queen’s University, Kingston, Ont.
MD MScLarry Nijmeh
Department of Family and Community Medicine (Hu, Nijmeh, Pyle), University of Toronto, Toronto, Ont.; Department of Emergency Medicine and Critical Care (Nijmeh, Pyle), Lakeridge Health, Oshawa, Ont.; Department of Family Medicine (Nijmeh, Pyle), Queen’s University, Kingston, Ont.
MDAdam Pyle
Department of Family and Community Medicine (Hu, Nijmeh, Pyle), University of Toronto, Toronto, Ont.; Department of Emergency Medicine and Critical Care (Nijmeh, Pyle), Lakeridge Health, Oshawa, Ont.; Department of Family Medicine (Nijmeh, Pyle), Queen’s University, Kingston, Ont.
MDArticle Figures & Tables
There are no figures or tables available.
In this issue
Article tools
Buprenorphine–naloxone
Tina Hu, Larry Nijmeh, Adam Pyle
CMAJ Nov 2018, 190 (47) E1389; DOI: 10.1503/cmaj.180776
Jump to section
- Article
- Buprenorphine–naloxone is first-line therapy for opioid use disorder in Canada
- Buprenorphine–naloxone should be offered in all care settings, including primary care, emergency departments and correctional facilities
- To initiate buprenorphine–naloxone, patients should ideally be in moderate opioid withdrawal
- Optimal buprenorphine–naloxone maintenance doses should prevent withdrawal symptoms for 24 hours
- All patients with opioid use disorder should have access to the full spectrum of treatments
- Acknowledgements
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.
Podcast